1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

In Brief

CHPA stands up for gluten in OTCs; Sen. Durbin targets energy drink supplement labeling; CDC report delves into U.S. nutritional data; P&G files tooth whitening patent suit against Be Well Health Marketing; more news In Brief.

Banning gluten-containing source ingredients from OTC drugs and dietary supplements unnecessarily would disrupt the supply chain and may limit the availability of important health care products in the U.S., the Consumer Healthcare Products Association argues. The trade group’s March 20 comment responds to FDA’s December request for information on gluten in drug products Also see "In Brief" - Pink Sheet, 9 January, 2012.. CHPA explains certain ingredients in OTC drugs and supplements are derived from wheat, barley and rye, which can sicken people with celiac disease. However, the association says the amount of gluten in finished OTCs where gluten is not intentionally added is “minute, especially when compared to intake via the food supply.” CHPA explains ingredient processing significantly reduces or eliminates gluten in the final product.

Sen. Dick Durbin requests FDA act against high-caffeine energy drinks following the December death of a Maryland 14-year-old who suffered...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More Telework, More Staff, US FDA’s Tidmarsh Plans To Alleviate Workforce Challenges

 
• By Sarah Karlin-Smith

The new CDER director focused on plans to improve morale during an Aug. 8 townhall, but staff comments indicate that may be a challenge.

US Pricing Reform: New Products Offer ‘On Ramp’ To Implementation, Lilly’s Ricks Says

 
• By Cathy Kelly

Eli Lilly's CEO argued that pricing reforms aimed at existing drugs would be “hard to sustain or justify,” while other companies suggested a growing interest in direct-to-consumer sales programs.

New US FDA CDER Director Pledges No Politics In Approvals, Adds Higher Ups Can Overturn

 
• By Sarah Karlin-Smith

New CDER Director George Tidmarsh promised to keep politics out of drug approvals, but suggested during a meeting with staff that he could not insulate the drug center from political pressures coming from those above him.

EU Must Up Competitiveness To Counter US Tariffs And Pricing Woes For SMEs

 
• By Francesca Bruce

Companies in Europe cannot delay business decision making much longer to wait for more certainty on major US policy shifts on tariffs and pricing.

More from North America

HHS mRNA Vaccine Funding Cut Impact Limited (And One Contract Isn’t Even mRNA)

 
• By Alaric DeArment

HHS' culling of mRNA vaccine projects under BARDA will heavily impact pandemic preparedness. Tiba Biotech was even “caught off guard” by its inclusion, because its project was neither a vaccine nor mRNA-based.

Manufacturers Can Keep Their Shoes On: FDA PreCheck To Streamline US Facility Applications

 
• By Derrick Gingery

The program would allow early interactions with FDA staff to speed construction and approval of pharmaceutical manufacturing facilities in the US, but will staff be available?

US FDA Requires Opioid Class Labeling Changes Despite Adcomm Advice

 
• By Kate Rawson

Quantitative estimates of the safety risks with opioid pain medication, including the risk of addiction and misuse, must be added to labeling.